IGF-1LR3 Kit
Price range: $50.00 through $255.00
(CAS 946870-92-4); supplier specifications (); structural studies by Francis GL et al. (1992); bioactivity data from FDC-P1 proliferation assays.
Description
🧪 Product Profile: IGF-1LR3
Product Name: IGF-1LR3 (Long-R3-IGF-I, Long Chain R3 Insulin-like Growth Factor-I)
CAS Number: 946870-92-4
Molecular Formula: C₃₉₀H₆₂₈N₁₁₀O₁₂₄S
Molecular Weight: ~9.9 kDa (83 amino acids)
Amino Acid Sequence: Modified human IGF-1 with an N-terminal 13-amino acid extension and substitution of Glu³ with Arg (R3), resulting in an 83-residue polypeptide.
Purity: ≥98% (HPLC verified) / ≥90% (SDS-PAGE)
Formulation: Lyophilized white powder (standard vials: 1mg, 5mg, 10mg)
🔬 Key Characteristics
IGF-1LR3 is a recombinant analog of insulin-like growth factor-1 (IGF-1) engineered for enhanced biological activity and reduced binding to IGF-binding proteins (IGFBPs). Developed in 1992, its structural modifications—an N-terminal 13-amino acid extension and Glu³→Arg substitution—significantly decrease IGFBP affinity, increasing free bioavailable concentrations by up to 10-fold compared to native IGF-1. This results in prolonged half-life and potent activation of the IGF-1 receptor (IGF-1R) in preclinical models.
⚙️ Mechanism of Action
- IGF-1R Activation: Binds with high affinity to IGF-1R, triggering receptor autophosphorylation and activation of downstream signaling cascades (PI3K/AKT and MAPK pathways).
- Cell Proliferation & Survival: Stimulates DNA synthesis, cell cycle progression (G1→S phase), and inhibits apoptosis via AKT-mediated suppression of pro-apoptotic proteins (e.g., Bax).
- Anabolic Effects: Promotes protein synthesis, muscle hypertrophy, and bone/cartilage growth by upregulating mTORC1 signaling.
- IGFBP Evasion: Reduced binding to IGFBPs (e.g., IGFBP-3) ensures sustained free ligand availability, avoiding sequestration and degradation.
📊 Research Applications
- Cell Biology: In vitro studies of cell growth, differentiation, and survival (e.g., muscle satellite cells, osteoblasts, neurons).
- Musculoskeletal Research: Models of muscle wasting, osteoporosis, and tissue regeneration.
- Oncology: Investigation of IGF-1R signaling in cancer cell proliferation and targeted therapy development.
- Metabolic Studies: Evaluation of insulin sensitivity, glucose uptake, and adipocyte metabolism.
💡 Product Features
- Bioactivity: Specific activity ≥1.0×10⁶ IU/mg (FDC-P1 cell proliferation assay), with ED₅₀ ≤2.0 ng/ml.
- Stability: Lyophilized form stable for 24 months at -20°C; reconstituted solutions (sterile water or PBS) stable for 2-7 days at 4°C.
- Expression System: Produced in E. coli or HEK293 cells, with options for His-tagged variants for purification.
- Low Cross-Reactivity: Minimal binding to insulin receptors, ensuring IGF-1R-specific signaling in research models.
⚠️ Disclaimer
For Research Use Only: Not approved for human or veterinary clinical use. Handling requires compliance with biosafety protocols for recombinant proteins, including proper reconstitution and disposal of contaminated materials.
Additional information
| FORMAT | 10Bottlex0.1mg, 10Bottlex1mg |
|---|





